SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, generated revenue of EUR 488.1 million in the first half of the 2026 financial year (October 1, 2025 – March 31, 2026), exceeding the previous year’s figure by 2.3 percent at constant currencies. The share of high-value solutions (HVS) in total sales rose to 56 percent (H1 2025: 55 percent). EBITDA remained almost unchanged at EUR 129.8 million, with a corresponding EBITDA margin of 26.6 percent (H1 2025: 27.0 percent).
“SCHOTT Pharma developed according to plan in the first half of the year and proved resilient even in a challenging global environment. The robustness of our business is rooted in our strategy of consistently focusing on high-margin high-value solutions. On this basis, we confirm our revenue and earnings forecast for the full year,” said Christian Mias, new CEO of SCHOTT Pharma since May 2026.
Reinhard Mayer, CFO of SCHOTT Pharma, added, “SCHOTT Pharma is growing profitably. We continue to invest in our capacities to meet the continued high demand for our solutions and advance our technological leadership. In addition, we saw a positive development in receivables in the first half of the year, which is reflected in a significant increase in free cash flow and thus a strengthened financial basis.”
Highlights
- Revenue in H1 2026 of EUR 488.1 million slightly above the previous year’s level (2.3 percent at constant currencies; reported: 1.0 percent)
- EBITDA margin at 26.6 percent (H1 2025: 27.0 percent)
- Revenue share of high-margin high-value solutions (HVS) increased to 56 percent (H1 2025: 55 percent)
- Free cash flow more than doubled to EUR 45.4 million
- Outlook for the 2026 financial year confirmed
The full report is available here.